April 1 (Reuters) - Lyell Immunopharma Inc LYEL.O:
LYELL IMMUNOPHARMA INC - TO CLOSE WEST HILLS MANUFACTURING FACILITY - SEC FILING
LYELL IMMUNOPHARMA INC - TO REDUCE WORKFORCE BY 73 EMPLOYEES IN WEST HILLS - SEC FILING
LYELL IMMUNOPHARMA INC - EXPECTS $3M-$4M EXPENSES FROM WORKFORCE REDUCTION - SEC FILING
LYELL IMMUNOPHARMA INC - LYFE MANUFACTURING CENTER PRODUCING IMPT-314 FOR PHASE 1/2 TRIAL - SEC FILING
LYELL IMMUNOPHARMA INC - LYFE MANUFACTURING CENTER EXPECTED TO MEET DRUG SUPPLY NEEDS - SEC FILING
LYELL IMMUNOPHARMA INC: REITERATES ITS FINANCIAL GUIDANCE
Source text: [ID:n0001193125-25-070521]
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.